NASDAQ:ITUS - ITUS Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$4.64
Today's Range$4.61 - $4.76
52-Week Range$1.83 - $6.43
Volume69,859 shs
Average Volume134,373 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
ITUS Corporation develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It also develops immuno-therapy drugs for the treatment of cancer. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. ITUS Corporation was founded in 1982 and is based in San Jose, California.

Receive ITUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Patent owners & lessors
SectorBusiness Services
Current SymbolNASDAQ:ITUS



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

ITUS (NASDAQ:ITUS) Frequently Asked Questions

What is ITUS's stock symbol?

ITUS trades on the NASDAQ under the ticker symbol "ITUS."

How were ITUS's earnings last quarter?

ITUS Corp (NASDAQ:ITUS) announced its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) EPS for the quarter. View ITUS's Earnings History.

Has ITUS been receiving favorable news coverage?

News articles about ITUS stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ITUS earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news coverage about the business services provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of ITUS's key competitors?

What other stocks do shareholders of ITUS own?

Who are ITUS's key executives?

ITUS's management team includes the folowing people:
  • Dr. Amit Kumar Ph.D., Exec. Chairman, Pres & CEO (Age 54)
  • Mr. Michael J. Catelani, COO, CFO & Corp. Sec. (Age 51)
  • Mr. John Roop, Sr. VP of Engineering (Age 68)
  • Mr. Anthony Campisi, VP of Engineering

How do I buy shares of ITUS?

Shares of ITUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ITUS's official website?

The official website for ITUS is

How can I contact ITUS?

ITUS's mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The business services provider can be reached via phone at 408-708-9808 or via email at [email protected]

MarketBeat Community Rating for ITUS (NASDAQ ITUS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about ITUS and other stocks. Vote "Outperform" if you believe ITUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by Staff

Featured Article: What are municipal bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel